CANSINOBIO(SH:688185)2025-01-17 10:10Financial Projections - The company expects to achieve an operating revenue of between 825 million and 865 million CNY for the year 2024[4] - The projected net profit attributable to the parent company for 2024 is expected to be between -335 million and -385 million CNY[4] - The net profit attributable to the parent company after deducting non-recurring gains and losses is projected to be between -395 million and -450 million CNY for 2024[4] Historical Performance - In 2023, the company reported an operating revenue of 357.08 million CNY and a net loss attributable to the parent company of -1.48 billion CNY[6] Business Development - The company has focused on advancing the commercialization of the meningococcal conjugate vaccine and the development of non-COVID vaccine products[7] - The company has improved its sales channels and the market share of its exclusive product, the ACYW135 meningococcal polysaccharide conjugate vaccine, is continuously increasing[7] Operational Efficiency - Management expenses and research and development expenses have decreased year-on-year, contributing to improved operational efficiency[7] - The company has optimized resource allocation and implemented cost reduction measures, leading to a significant decrease in asset impairment losses compared to the previous year[7] Earnings Forecast Accuracy - There are no significant uncertainties affecting the accuracy of this earnings forecast[8] - The data provided is preliminary and the final audited financial data will be disclosed in the official annual report for 2024[9]